Krissy Kull

You are sleeping poorly, snapping at people you love, and running hot at two in the morning. Your cycles have become unpredictable. You feel like a stranger in your own body. And yet, when you bring it up with your doctor, the response is something like: “You’re probably just stressed.”

Semaglutide and tirzepatide are injectable medications taken once weekly for chronic weight management in eligible adults. While both medications can support weight loss, they work differently, have different FDA-labeled indications, and have shown different average results in major clinical trials.

Weight loss medications have become an important part of many treatment plans for people managing overweight or obesity. In recent years, newer medications that affect appetite and metabolism have gained attention for their potential role in supporting weight management alongside lifestyle changes and medical guidance.

IV therapy has become an increasingly visible topic in sports recovery conversations, with athletes exploring a range of approaches to support hydration, nutrient balance, and overall recovery. While vitamin drips are often discussed in training

Metabolic health is not just about weight. It includes blood sugar control, insulin sensitivity, blood pressure, cholesterol, triglycerides, liver fat, sleep, and inflammation. With obesity rates still high in the U.S. and many states reporting adult prevalence at or above 35%, more people are looking for medical support that feels effective but tolerable.

GLP-1 microdosing is an emerging, more gradual approach to metabolic support that uses significantly lower, often customized doses of GLP-1 medications. This is commonly discussed in ranges like semaglutide 0.125 to 0.25 mg weekly, to improve tolerability while supporting appetite control and insulin sensitivity for some individuals.